Newsletter

950160 - Kolon Tissue Gene, Inc.

950160 Summary
Biopharma
Stock Price & Overview
₩17,100 +190 (+1.12%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩17,100  ≈ US$12  ·  Market cap ₩1.5tn (≈ $1.0bn)
Home › 950160 › Filings

Material matter affecting investment judgment (clinical trial result)

DART
Kolon Tissue Gene, Inc.
Filed Jul 20, 2026 KST · Filing · receipt 20260720900587

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험결과) (TGC 15302 Study 탑라인 데이터 )

950160

Price
₩17,100
Change
+1.12%
Market cap
₩1.5tn
Prev. close
₩16,910
950160 SummaryCompare to Peers

More 950160 filings

Half-Year Report

08/14/26

5% Ownership Report — Large Holdings

08/07/26

Insider / Major Shareholder Holdings Report

08/06/26

5% Ownership Report — Large Holdings

07/31/26

5% Ownership Report — Large Holdings

07/28/26

Insider / Major Shareholder Holdings Report ×3

07/27/26